Sevabertinib Shows Antitumour Activity in Patients with Locally Advanced or Metastatic HER2-mutated NSCLC By Ogkologos - November 14, 2025 182 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SOHO-01 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR A Favourable Benefit-Risk Profile for Taletrectinib in TKI-Naїve and Crizotinib-Pretreated Patients... July 24, 2024 Activity of Alectinib for ALK-Rearranged Metastatic Solid Tumours, Other Than NSCLC April 19, 2022 Lung cancer screening can’t leave anyone in the UK behind July 27, 2023 Capmatinib Shows Activity in Advanced NSCLC with a MET Exon 14... September 8, 2020 Load more HOT NEWS Potential Value of ctDNA NGS-based Analysis of Imatinib Resistant Secondary KIT... Long-Term Outcomes from the CheckMate 067 Study in Patients With Advanced... Trastuzumab Deruxtecan Shows Promising Activity Among Patients with HER2-positive and Signal... 9 Ways to Use Social Media for Support Throughout Your Cancer...
